In August, gene therapy's turbulent ride through the clinical rapids took a new twist as Ark Therapeutics released positive top-line results from a phase 3 trial of its adenoviral gene therapy ...

Gene therapy trailblazer Ark Therapeutics was dealt a blow last December, when the European Medicines Agency (EMEA) rejected the London-based company's marketing application for its adenoviral ...

It also chides the government for imposing generous restrictions for the testing and use of gene-spliced plants, but not of new varieties produced by traditional techniques. “Regulatory considerations ...